These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 12535234)

  • 21. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3.
    Siebert U; Alagoz O; Bayoumi AM; Jahn B; Owens DK; Cohen DJ; Kuntz KM;
    Value Health; 2012; 15(6):812-20. PubMed ID: 22999130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.
    Drummond M; Barbieri M; Cook J; Glick HA; Lis J; Malik F; Reed SD; Rutten F; Sculpher M; Severens J
    Value Health; 2009 Jun; 12(4):409-18. PubMed ID: 19900249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to develop cost-conscious guidelines.
    Eccles M; Mason J
    Health Technol Assess; 2001; 5(16):1-69. PubMed ID: 11427188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Value Health; 2012; 15(6):843-50. PubMed ID: 22999134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.
    Siebert U; Alagoz O; Bayoumi AM; Jahn B; Owens DK; Cohen DJ; Kuntz KM
    Med Decis Making; 2012; 32(5):690-700. PubMed ID: 22990084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.
    Mauskopf J; Standaert B; Connolly MP; Culyer AJ; Garrison LP; Hutubessy R; Jit M; Pitman R; Revill P; Severens JL
    Value Health; 2018 Oct; 21(10):1133-1149. PubMed ID: 30314613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report.
    Wailoo AJ; Hernandez-Alava M; Manca A; Mejia A; Ray J; Crawford B; Botteman M; Busschbach J
    Value Health; 2017 Jan; 20(1):18-27. PubMed ID: 28212961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The quality of three decision-analytic diabetes models: a systematic health economic assessment.
    Becker C; Langer A; Leidl R
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):751-62. PubMed ID: 22098291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
    Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
    Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mathematical models in decision analysis.
    Tom E; Schulman KA
    Infect Control Hosp Epidemiol; 1997 Jan; 18(1):65-73. PubMed ID: 9013249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV.
    Mullins CD; Seal B; Seoane-Vazquez E; Sankaranarayanan J; Asche CV; Jayadevappa R; Lee WC; Romanus DK; Wang J; Hay JW; Smeeding J
    Value Health; 2010; 13(1):18-24. PubMed ID: 19807903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
    Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
    Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.
    Marshall DA; Burgos-Liz L; IJzerman MJ; Crown W; Padula WV; Wong PK; Pasupathy KS; Higashi MK; Osgood ND;
    Value Health; 2015 Mar; 18(2):147-60. PubMed ID: 25773550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.
    Jansen JP; Fleurence R; Devine B; Itzler R; Barrett A; Hawkins N; Lee K; Boersma C; Annemans L; Cappelleri JC
    Value Health; 2011 Jun; 14(4):417-28. PubMed ID: 21669366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Where are we at with model-based economic evaluations of interventions for dementia? a systematic review and quality assessment.
    Nguyen KH; Comans TA; Green C
    Int Psychogeriatr; 2018 Nov; 30(11):1593-1605. PubMed ID: 30475198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.